CRVSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Corvus Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$9.65+0.13 (+1.37%)
Close on Oct 19, 2026
- Market cap
- $891.35M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
84.1%
71M of 84M shares
Institutional holders
174
41 new, 30 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
3 buys · 0 sales
Net bought $333.65K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Orbimed Advisors LLC | 8,609,091 | 10.30% | 13D (active) amendment | Jan 23, 2026 |
| Alex Silverstein | 6,831,828 | 7.50% | 13G (passive) | Mar 31, 2026 |
| BlackRock, Inc. | 6,325,157 | 7.50% | 13G (passive) amendment | Jun 30, 2026 |
| Richard A. Miller | 6,085,922 | 7.80% | 13G (passive) amendment | Dec 31, 2025 |
| State Street Corporation | 4,474,091 | 5.30% | 13G (passive) | Jun 30, 2026 |
| Samlyn, LP | 4,065,935 | 6.00% | 13G (passive) amendment | Mar 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CRVS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Orbimed Advisors LLC | 7,165,006 | 8.52% | $107.05M | – | 1.98% |
| BlackRock, Inc. | 7,138,811 | 8.49% | $106.65M | +978,389 | 0.00% |
| State Street Corp | 4,474,091 | 5.32% | $66.84M | +908,099 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 3,789,126 | 4.50% | $56.61K | +871,826 | 0.01% |
| Vanguard Capital Management LLC | 3,292,710 | 3.91% | $49.19M | +58,172 | 0.00% |
| Adams Street Partners LLC | 3,275,616 | 3.89% | $48.94M | – | 11.06% |
| Vivo Capital, LLC | 2,805,816 | 3.34% | $41.92M | – | 3.83% |
| Wellington Management Group Llp | 2,731,632 | 3.25% | $40.81M | +413,115 | 0.01% |
| Perceptive Advisors LLC | 2,667,441 | 3.17% | $39.85M | +375,000 | 0.60% |
| Deep Track Capital, LP | 2,491,939 | 2.96% | $37.23M | +400 | 0.54% |
| Braidwell LP | 2,126,298 | 2.53% | $31.77M | +373,500 | 1.18% |
| Geode Capital Management, LLC | 1,853,659 | 2.20% | $27.70M | +140,918 | 0.00% |
| Foresite Capital Management VI LLC | 1,831,233 | 2.18% | $27.36M | – | 4.26% |
| Goldman Sachs Group Inc | 1,576,352 | 1.87% | $23.55M | +35,543 | 0.00% |
| Hood River Capital Management LLC | 1,571,805 | 1.87% | $23.48M | +236,696 | 0.17% |
| Morgan Stanley | 1,344,736 | 1.60% | $20.09M | −1,154,089 | 0.00% |
| Boxer Capital Management, LLC | 1,100,000 | 1.31% | $16.43M | – | 1.24% |
| Catalio Capital Management, LP | 1,080,888 | 1.28% | $16.15M | +188,955 | 3.03% |
| Millennium Management LLC | 1,047,985 | 1.25% | $15.66M | +181,623 | 0.01% |
| Vanguard Portfolio Management LLC | 814,750 | 0.97% | $12.17M | +144,855 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 174 | 71M | 84.1% | 41 / 70 | 40 / 30 | 10M | 9M |
| Q1 2026 | 164 | 70M | 83.3% | 68 / 55 | 30 / 26 | 35M | 8M |
| Q4 2025 | 124 | 47M | 55.6% | 30 / 42 | 28 / 7 | 13M | 8M |
| Q3 2025 | 102 | 42M | 49.6% | 23 / 34 | 17 / 13 | 3M | 3M |
| Q2 2025 | 92 | 42M | 49.8% | 33 / 32 | 10 / 29 | 14M | 9M |
| Q1 2025 | 88 | 36M | 43.1% | 16 / 26 | 23 / 13 | 4M | 5M |
| Q4 2024 | 85 | 38M | 44.9% | 32 / 30 | 12 / 8 | 12M | 4M |
| Q3 2024 | 62 | 30M | 35.8% | 19 / 17 | 9 / 3 | 6M | 3M |
| Q2 2024 | 47 | 28M | 32.8% | 7 / 11 | 11 / 7 | 10M | 1M |
| Q1 2024 | 47 | 19M | 22.0% | 7 / 11 | 13 / 8 | 1M | 2M |
| Q4 2023 | 48 | 19M | 23.1% | 3 / 13 | 11 / 7 | 1M | 1M |
| Q3 2023 | 52 | 19M | 22.8% | 10 / 15 | 12 / 10 | 1M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of CRVS | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,931,644 | 3.49% | $43.80M | 0.41% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 2,374,106 | 2.82% | $35.47M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,748,043 | 2.08% | $26.12M | 0.03% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 963,958 | 1.15% | $14.40M | 0.10% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 844,722 | 1.00% | $12.62M | 0.01% | Jun 30, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 801,900 | 0.95% | $11.98M | 0.12% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 740,514 | 0.88% | $9.82M | 0.03% | Jul 31, 2026 |
| Hood River Small-Cap Growth Fund | 707,193 | 0.84% | $10.57M | 0.16% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 625,770 | 0.74% | $9.35M | 0.06% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 616,391 | 0.73% | $9.21M | 0.08% | Jun 30, 2026 |
| iShares Biotechnology ETF | 445,673 | 0.53% | $6.66M | 0.07% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 380,913 | 0.45% | $4.73M | 0.01% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 330,863 | 0.39% | $4.11M | 0.02% | May 31, 2026 |
| Vanguard Explorer Fund | 290,675 | 0.35% | $3.85M | 0.02% | Jul 31, 2026 |
| iShares Micro-Cap ETF | 223,599 | 0.27% | $3.34M | 0.22% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Richard A. Miller Md | President and CEO, Director | 2,331,742 | 2.77% | May 20, 2026 |
| Leiv Lea | Chief Financial Officer | 282,444 | 0.34% | Dec 8, 2025 |
| William Benton Jones | See Remarks | 173,130 | 0.21% | Dec 8, 2025 |
| Jeffrey Arcara | Chief Business Officer | – | – | Dec 8, 2025 |
| den Broek Richard van | Director | 160,000 | 0.19% | Jun 15, 2026 |
| David Scott Moore | Director | 21,700 | 0.03% | Jun 15, 2026 |
| Linda Grais | Director | 10,000 | 0.01% | Jun 15, 2026 |
| Peter A. Thompson | Director, 10% owner | 8,729,091 | 10.38% | Jun 15, 2026 |
| Ian T. Clark | Director | – | – | Jun 15, 2026 |
| Andrew C. Chan | Director | – | – | Apr 27, 2026 |
| Capital GP V. LLC OrbiMed | Director, 10% owner | 6,943,654 | 8.25% | Jul 1, 2025 |
| Advisors Llc Orbimed | Director, 10% owner | 8,341,338 | 9.92% | Jul 1, 2025 |
| Scott W. Morrison | Director | – | – | Jun 16, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| David Scott Moore Director | Jun 11, 2026 | Buy | +21,700 | $11.53 | $250.20K | 21,700 |
| Richard A. Miller Md President and CEO, Director | May 18, 2026 | Buy | +1,932 | $12.01 | $23.20K | 1,195,035 |
| Richard A. Miller Md President and CEO, Director | May 18, 2026 | Buy | +5,000 | $12.05 | $60.25K | 1,193,103 |
| Peter A. Thompson Director, 10% owner | Jan 28, 2026 | Option exercise | +15,000 | $2.74 | $41.10K | 120,000 |
| Peter A. Thompson Director, 10% owner | Jan 28, 2026 | Option exercise | +15,000 | $1.64 | $24.60K | 195,000 |
| Peter A. Thompson Director, 10% owner | Jan 28, 2026 | Option exercise | +15,000 | $2.49 | $37.35K | 180,000 |
| Peter A. Thompson Director, 10% owner | Jan 28, 2026 | Option exercise | +15,000 | $0.97 | $14.55K | 165,000 |
| Peter A. Thompson Director, 10% owner | Jan 28, 2026 | Option exercise | +15,000 | $0.99 | $14.85K | 150,000 |
| Peter A. Thompson Director, 10% owner | Jan 28, 2026 | Option exercise | +15,000 | $2.60 | $39.00K | 135,000 |
| Peter A. Thompson Director, 10% owner | Jan 28, 2026 | Option exercise | +15,000 | $2.12 | $31.80K | 210,000 |
| Peter A. Thompson Director, 10% owner | Jan 28, 2026 | Option exercise | +15,000 | $3.27 | $49.05K | 105,000 |
| Peter A. Thompson Director, 10% owner | Jan 28, 2026 | Option exercise | +15,000 | $2.00 | $30.00K | 90,000 |
| Peter A. Thompson Director, 10% owner | Jan 28, 2026 | Option exercise | +15,000 | $3.61 | $54.15K | 75,000 |
| Peter A. Thompson Director, 10% owner | Jan 28, 2026 | Option exercise | +15,000 | $12.50 | $187.50K | 60,000 |
| Peter A. Thompson Director, 10% owner | Jan 28, 2026 | Option exercise | +15,000 | $9.70 | $145.50K | 45,000 |
| Peter A. Thompson Director, 10% owner | Jan 28, 2026 | Option exercise | +30,000 | $15.00 | $450.00K | 30,000 |
| Advisors Llc Orbimed Director, 10% owner | Jun 27, 2025 | Option exercise | +1,397,684 | $3.50 | $4.89M | 8,341,338 |
| Advisors Llc Orbimed Director, 10% owner | Jun 27, 2025 | Sale | −1,176,332 | $4.16 | $4.89M | 7,165,006 |
| Peter A. Thompson Director, 10% owner | Jun 27, 2025 | Sale | −1,176,332 | $4.16 | $4.89M | 7,165,006 |
| Peter A. Thompson Director, 10% owner | Jun 27, 2025 | Option exercise | +1,397,684 | $3.50 | $4.89M | 8,341,338 |
| William Benton Jones See Remarks | Jun 4, 2025 | Option exercise | +19,357 | $3.50 | $67.75K | 173,130 |
| Richard A. Miller Md President and CEO, Director | May 7, 2025 | Option exercise | +559,073 | $3.50 | $1.96M | 1,136,707 |
| Richard A. Miller Md President and CEO, Director | May 10, 2024 | Gift | −302,016 | – | – | 1,188,103 |
| William Benton Jones See Remarks | May 6, 2024 | Buy | +20,000 | $1.73 | $34.60K | 153,773 |
| Richard A. Miller Md President and CEO, Director | May 6, 2024 | Buy | +577,634 | $1.73 | $999.31K | 577,634 |
| Linda Grais Director | May 15, 2023 | Buy | +10,000 | $2.45 | $24.50K | 10,000 |
| William Benton Jones See Remarks | Dec 20, 2022 | Buy | +20,000 | $0.79 | $15.80K | 133,773 |
| Richard A. Miller Md President and CEO, Director | Dec 14, 2022 | Buy | +10,000 | $0.78 | $7.80K | 1,490,119 |
| Leiv Lea Chief Financial Officer | Dec 14, 2022 | Buy | +4,000 | $0.84 | $3.36K | 133,238 |
| Richard A. Miller Md President and CEO, Director | Dec 13, 2022 | Buy | +50,000 | $0.74 | $37.00K | 1,480,119 |
| Leiv Lea Chief Financial Officer | Dec 13, 2022 | Buy | +30,000 | $0.74 | $22.20K | 129,238 |
| Richard A. Miller Md President and CEO, Director | Sep 28, 2022 | Buy | +25,000 | $0.76 | $19.00K | 1,394,405 |
| Richard A. Miller Md President and CEO, Director | Sep 20, 2022 | Buy | +12,300 | $0.81 | $9.96K | 1,361,705 |
| Richard A. Miller Md President and CEO, Director | Sep 20, 2022 | Buy | +5,000 | $0.82 | $4.10K | 1,369,405 |
| Richard A. Miller Md President and CEO, Director | Sep 20, 2022 | Buy | +2,700 | $0.82 | $2.21K | 1,364,405 |
| Richard A. Miller Md President and CEO, Director | Jun 27, 2022 | Buy | +5,000 | $1.00 | $5.00K | 1,349,405 |
| Richard A. Miller Md President and CEO, Director | Jun 24, 2022 | Buy | +5,000 | $1.03 | $5.15K | 1,344,405 |
| Richard A. Miller Md President and CEO, Director | Jun 6, 2022 | Buy | +890 | $1.01 | $899 | 1,339,405 |
| Richard A. Miller Md President and CEO, Director | Jun 2, 2022 | Buy | +170 | $0.97 | $165 | 1,338,515 |
| Richard A. Miller Md President and CEO, Director | Jun 2, 2022 | Buy | +4,830 | $0.98 | $4.73K | 1,338,345 |
| Richard A. Miller Md President and CEO, Director | Mar 31, 2022 | Buy | +15,000 | $1.64 | $24.60K | 1,333,515 |
| Richard A. Miller Md President and CEO, Director | Mar 17, 2022 | Buy | +5,000 | $1.59 | $7.95K | 1,318,515 |
| Leiv Lea Chief Financial Officer | Mar 17, 2022 | Buy | +13,878 | $1.65 | $22.90K | 99,238 |
| Leiv Lea Chief Financial Officer | Mar 16, 2022 | Buy | +35,160 | $1.54 | $54.15K | 85,360 |
| Richard A. Miller Md President and CEO, Director | Mar 15, 2022 | Buy | +25,000 | $1.47 | $36.75K | 1,313,515 |
| EcoR1 Capital, LLC 10% owner | Oct 1, 2021 | Sale | −2,000,000 | $4.96 | $9.92M | 81,077 |
| EcoR1 Capital, LLC 10% owner | Sep 30, 2021 | Sale | −3,000,000 | $5.04 | $15.12M | 2,081,077 |
| Peter A. Thompson Director, 10% owner | Sep 20, 2021 | Sale | −1,109,644 | $6.09 | $6.76M | 6,943,654 |
| Capital GP V. LLC OrbiMed Director, 10% owner | Sep 20, 2021 | Sale | −1,109,644 | $6.09 | $6.76M | 6,943,654 |
| Richard A. Miller Md President and CEO, Director | Aug 20, 2021 | Buy | +10,000 | $1.93 | $19.30K | 1,288,515 |
| Richard A. Miller Md President and CEO, Director | May 4, 2021 | Buy | +35,714 | $2.80 | $100.00K | 35,714 |
| Peter A. Thompson Director, 10% owner | Feb 17, 2021 | Buy | +1,285,714 | $3.50 | $4.50M | 8,053,298 |
| Advisors Llc Orbimed Director, 10% owner | Feb 17, 2021 | Buy | +1,285,714 | $3.50 | $4.50M | 8,053,298 |
| Richard A. Miller Md President and CEO, Director | Feb 17, 2021 | Buy | +100,000 | $3.50 | $350.00K | 1,278,515 |
| Holdings A/S Novo 10% owner | Jul 8, 2020 | Sale | −741,440 | $5.37 | $3.98M | 1,389,498 |
| Holdings A/S Novo 10% owner | Jul 7, 2020 | Sale | −796,622 | $5.25 | $4.18M | 2,130,938 |
| Richard A. Miller Md President and CEO, Director | Nov 13, 2019 | Buy | +14,736 | $3.00 | $44.21K | 1,178,515 |
| Richard A. Miller Md President and CEO, Director | Nov 12, 2019 | Buy | +272 | $2.90 | $789 | 1,163,779 |
| Richard A. Miller Md President and CEO, Director | Aug 7, 2019 | Buy | +2,500 | $3.54 | $8.85K | 1,163,507 |
| Capital GP V. LLC OrbiMed Director, 10% owner | Aug 6, 2019 | Buy | +142,656 | $3.51 | $500.72K | 6,767,584 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.